Anonymity: What does it mean and why is it important to anonymous living liver donors?

Sapna Humar, Judy Jung, Sandra Krause, Nazia Selzner, Susan Abbey – 28 February 2022 – Anonymous living organ donation has recently become more common in select transplantation programs, with donors voluntarily offering a kidney or a lobe of their liver to those in need. These anonymous donations may be directed to a specific recipient or nondirected, and anonymity may be one way or reciprocal. Given their unique situation, we interviewed a cohort of anonymous living liver donors and explored their opinions surrounding anonymity and its implications in living liver donation.

Cholestatic liver diseases of genetic etiology: Advances and controversies

Samar H. Ibrahim, Binita M. Kamath, Kathleen M. Loomes, Saul J. Karpen – 28 February 2022 – With the application of modern investigative technologies, cholestatic liver diseases of genetic etiology are increasingly identified as the root cause of previously designated “idiopathic” adult and pediatric liver diseases. Here, we review advances in the field enhanced by a deeper understanding of the phenotypes associated with specific gene defects that lead to cholestatic liver diseases.

Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation

Lydia Sastre, Raquel García, Clara Viñals, Antonio J. Amor, Gema Yago, Alicia Hervás, Lorena Sánchez, Joan Trabal, Judit Molero, Laia Escudé, Giulia Pagano, Miquel Blasco, Rosa Gilabert, Pablo Ruiz, Jordi Colmenero, Miquel Navasa, Emilio Ortega, Gonzalo Crespo – 27 February 2022 – Although liver transplantation (LT) recipients are at high cardiovascular risk (CVR), the management of CVR factors (CVRF) after LT is far from optimal and needs to be improved.

National experience with living donor liver transplantation for hepatocellular carcinoma

Jordyn Silverstein, Francis Y. Yao, Joshua D. Grab, Hillary J. Braun, John Roberts, Jennifer L. Dodge, Neil Mehta – 27 February 2022 – Living donor liver transplantation (LDLT) is an attractive option to decrease waitlist dropout, particularly for patients with hepatocellular carcinoma (HCC) who face lengthening waiting times. Using the United Network for Organ Sharing (UNOS) national database, trends in LDLT utilization for patients with HCC were evaluated, and post‐LT outcomes for LDLT versus deceased donor liver transplantation (DDLT) were compared.

Subscribe to